P/E ratio for Pharma Mar (PHM.MC)
P/E ratio as of April 2024 (TTM): 25.7
According to Pharma Mar's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.7432. At the end of 2022 the company had a P/E ratio of 23.5.
P/E ratio history for Pharma Mar from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 23.5 | 111.75% |
| 2021 | 11.1 | 16.75% |
| 2020 | 9.52 | -113.75% |
| 2019 | -69.2 | 58.93% |
| 2018 | -43.6 | 112.44% |
| 2017 | -20.5 | -17.63% |
| 2016 | -24.9 | -129.85% |
| 2015 | 83.4 | 85.7% |
| 2014 | 44.9 | -0.01% |
| 2013 | 44.9 | -36.22% |
| 2012 | 70.4 | -107.28% |
| 2011 | -968 | 1063.67% |
| 2010 | -83.2 | 159.26% |
| 2009 | -32.1 | 81.97% |
| 2008 | -17.6 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.